A Digital Intervention (ACT on Vaping App) for Vaping Cessation in Young Adult E-Cigarette Users
Launched by FRED HUTCHINSON CANCER CENTER · Mar 27, 2025
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a smartphone app called ACT on Vaping, designed to help young adults quit using e-cigarettes. The app uses a type of therapy called Acceptance and Commitment Therapy (ACT) to support users in recognizing what triggers their vaping habits and teaches them how to manage these triggers effectively. It aims to provide a convenient and modern way for young adults, who often prefer digital solutions, to find help in quitting nicotine and tobacco products.
To participate in this trial, you need to be between 18 and 30 years old, have been using e-cigarettes regularly for at least the past month, and have a smartphone that meets certain requirements. You’ll need to be comfortable using apps and have access to the internet or mobile data. Participants will download the ACT on Vaping app and engage with its sessions to help them quit. This trial is not currently recruiting but will soon be looking for individuals who meet these criteria to take part in this important research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18-30
- • Age of majority (to provide informed consent) in current state/territory of residence
- • Current weekly user of e-cigarette product(s) for the last 30 days
- • Has a smartphone; either an Android (running version 12 or higher) or iPhone (running iOS version 17 or higher, iPhone 11 or more recent)
- • Experience downloading and using one or more apps on their smartphone
- • Have a mobile data plan and/or access to WiFi to support the use of the ACT on Vaping app
- • Has access to text messaging
- • Has an email address
- • United States (US) resident, with a US mailing address
- • Willing to complete all study procedures
- • Comfortable reading and writing in English
- Exclusion Criteria:
- • Currently using other tobacco cessation treatments at the time of screening, including pharmacotherapy or behavioral support (note: use of these treatment is allowable during trial participation)
- • Member of the same household as another research participant
- • Currently in prison
- • Google voice number as sole phone number, due to its association with fraudulent study entry attempts
- • Is ineligible per fraud prevention protocol
- • Employees/family of investigator or study center
About Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center is a leading nonprofit research institution dedicated to the pursuit of innovative cancer treatments and prevention strategies. Established in Seattle, Washington, the center is renowned for its pioneering work in hematopoietic cell transplantation and its commitment to advancing cancer research through collaborative clinical trials. By integrating cutting-edge science with compassionate patient care, Fred Hutchinson Cancer Center aims to improve outcomes for patients while fostering a multidisciplinary approach to tackling complex cancer challenges. With a strong emphasis on translating research findings into clinical applications, the center is at the forefront of developing novel therapies that offer hope to patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Patients applied
Trial Officials
Jaimee Heffner, PhD
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported